A coronavirus vaccine candidate similar to that of recently approved ones from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) has now moved into late-stage testing on healthcare workers.
CureVac (NASDAQ:CVAC), like BioNTech a clinical-stage biotech based in Europe, announced Monday that its CvnCoV is about to enter phase 3 clinical trials, in testing that involves healthcare workers. The first participant in the study is to be administered the initial shot of the vaccine candidate on Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,